Compounds > ranolazine

Page last updated: 2024-08-24

ranolazine and sotalol

ranolazine has been researched along with sotalol in 15 studies

Research

Studies (15)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	14 (93.33)	24.3611
2020's	1 (6.67)	2.80

Authors

Authors	Studies
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Guo, D; Jia, S; Lian, J; Ma, A; Patel, C; Xue, X; Yan, GX; Yang, L; Yuan, Z	1
Bhandari, A; Dow, JS; Kloner, RA	1
Anderson, JL; Bair, TL; Bunch, TJ; Crandall, BG; Day, JD; Lappe, DL; Mader, KM; Mahapatra, S; May, HT; Molden, J; Muhlestein, JB; Murdock, D; Osborn, JS; Weiss, JP	1
Antzelevitch, C; Gibson, JK; Lynch, JJ; Pourrier, M; Sicouri, S	1
Franz, MR; Singh, SN	1
Antzelevitch, C; Burashnikov, A; Gibson, JK; Lynch, JJ; Pourrier, M	1
Belardinelli, L; Breithardt, G; Eckardt, L; Frommeyer, G; Grundmann, F; Milberg, P; Osada, N; Rajamani, S; Stypmann, J	1
Belardinelli, L; Breithardt, G; Eckardt, L; Frommeyer, G; Ghezelbash, S; Milberg, P; Osada, N; Rajamani, S; Razvan, R	1
Breithardt, G; Eckardt, L; Frommeyer, G; Kaese, S; Kaiser, D; Milberg, P; Uphaus, T	1
Clauss, C; Eckardt, L; Frommeyer, G; Grotthoff, JS; Grundmann, F; Kaese, S; Milberg, P; Pott, C; Ramtin, S; Schmidt, M	1
Lüthje, L; Maier, LS; Seegers, J; Sohns, C; Sossalla, S; Toischer, K; Vollmann, D; Wallisch, N; Zabel, M	1
Al-Khatib, SM; Allen LaPointe, NM; Curtis, LH; Hammill, BG; Mi, X; Pokorney, SD	1
Kawai, T; Kuninishi, Y; Muraki, Y; Nogawa, H	1

Reviews

1 review(s) available for ranolazine and sotalol

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Other Studies

14 other study(ies) available for ranolazine and sotalol

Article	Year
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10 Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection	2012
Modulation of the late sodium current by ATX-II and ranolazine affects the reverse use-dependence and proarrhythmic liability of IKr blockade. British journal of pharmacology, 2011, Volume: 164, Issue:2 Topics: Acetanilides; Animals; Anti-Arrhythmia Agents; Clarithromycin; Cnidarian Venoms; Heart Ventricles; Piperazines; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Rabbits; Ranolazine; Sodium Channels; Sotalol; Torsades de Pointes	2011
First direct comparison of the late sodium current blocker ranolazine to established antiarrhythmic agents in an ischemia/reperfusion model. Journal of cardiovascular pharmacology and therapeutics, 2011, Volume: 16, Issue:2 Topics: Acetanilides; Animals; Anti-Arrhythmia Agents; Enzyme Inhibitors; Female; Infusions, Intravenous; Injections, Intravenous; Lidocaine; Myocardial Reperfusion Injury; Piperazines; Random Allocation; Ranolazine; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Sotalol; Statistics, Nonparametric; Tachycardia, Ventricular; Ventricular Fibrillation	2011
Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks. Pacing and clinical electrophysiology : PACE, 2011, Volume: 34, Issue:12 Topics: Acetanilides; Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathy, Dilated; Cohort Studies; Defibrillators, Implantable; Drug Therapy, Combination; Electric Countershock; Electrocardiography; Female; Humans; Hypoglycemia; Lidocaine; Male; Mexiletine; Middle Aged; Myocardial Ischemia; Piperazines; Ranolazine; Sotalol; Stroke Volume; Tachycardia, Ventricular; Treatment Outcome	2011
Comparison of electrophysiological and antiarrhythmic effects of vernakalant, ranolazine, and sotalol in canine pulmonary vein sleeve preparations. Heart rhythm, 2012, Volume: 9, Issue:3 Topics: Acetanilides; Action Potentials; Adrenergic beta-Agonists; Animals; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Biological Availability; Cardiac Electrophysiology; Cell Membrane; Dogs; Heart Rate; Humans; Isoproterenol; Membrane Potentials; Piperazines; Pulmonary Veins; Pyrrolidines; Ranolazine; Sodium Channels; Sotalol	2012
Comparative pharmacophysiology of vernakalant, ranolazine, and d-sotalol in canine pulmonary vein sleeve preparations: new flavors or same old taste? Heart rhythm, 2012, Volume: 9, Issue:3 Topics: Acetanilides; Animals; Anisoles; Atrial Fibrillation; Humans; Piperazines; Pulmonary Veins; Pyrrolidines; Ranolazine; Sodium Channels; Sotalol	2012
Rate-dependent effects of vernakalant in the isolated non-remodeled canine left atria are primarily due to block of the sodium channel: comparison with ranolazine and dl-sotalol. Circulation. Arrhythmia and electrophysiology, 2012, Volume: 5, Issue:2 Topics: Acetanilides; Action Potentials; Animals; Anisoles; Anti-Arrhythmia Agents; Dogs; Female; Heart Atria; In Vitro Techniques; Male; Models, Animal; Piperazines; Pyrrolidines; Ranolazine; Refractory Period, Electrophysiological; Sodium Channel Blockers; Sodium Channels; Sotalol; Time Factors	2012
New insights into the beneficial electrophysiologic profile of ranolazine in heart failure: prevention of ventricular fibrillation with increased postrepolarization refractoriness and without drug-induced proarrhythmia. Journal of cardiac failure, 2012, Volume: 18, Issue:12 Topics: Acetanilides; Action Potentials; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Electrocardiography; Heart Failure; Piperazines; Rabbits; Ranolazine; Refractory Period, Electrophysiological; Sotalol; Ventricular Fibrillation	2012
Sodium channel block by ranolazine in an experimental model of stretch-related atrial fibrillation: prolongation of interatrial conduction time and increase in post-repolarization refractoriness. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2013, Volume: 15, Issue:5 Topics: Acetanilides; Administration, Oral; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Flecainide; Heart Conduction System; Heart Rate; In Vitro Techniques; Neural Conduction; Piperazines; Rabbits; Ranolazine; Refractory Period, Electrophysiological; Sodium Channel Blockers; Sotalol; Treatment Outcome	2013
Antiarrhythmic effect of ranolazine in combination with class III drugs in an experimental whole-heart model of atrial fibrillation. Cardiovascular therapeutics, 2013, Volume: 31, Issue:6 Topics: Acetanilides; Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Models, Animal; Dronedarone; Drug Therapy, Combination; Female; Piperazines; Rabbits; Ranolazine; Refractory Period, Electrophysiological; Sotalol	2013
Electrophysiological profile of vernakalant in an experimental whole-heart model: the absence of proarrhythmia despite significant effect on myocardial repolarization. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2014, Volume: 16, Issue:8 Topics: Acetanilides; Action Potentials; Animals; Anisoles; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrophysiologic Techniques, Cardiac; Heart Conduction System; In Vitro Techniques; Models, Animal; Perfusion; Piperazines; Potassium Channel Blockers; Pyrrolidines; Rabbits; Ranolazine; Risk Assessment; Risk Factors; Sodium Channel Blockers; Sotalol; Time Factors	2014
Effects of ranolazine on torsades de pointes tachycardias in a healthy isolated rabbit heart model. Cardiovascular therapeutics, 2014, Volume: 32, Issue:4 Topics: Acetanilides; Action Potentials; Animals; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Dose-Response Relationship, Drug; Heart Conduction System; Heart Rate; In Vitro Techniques; Perfusion; Piperazines; Potassium; Rabbits; Ranolazine; Sotalol; Time Factors; Torsades de Pointes	2014
Use of Antiarrhythmic Medications in Medicare Part D Patients With an Implantable Cardioverter-Defibrillator and Ventricular Tachycardia. The American journal of cardiology, 2017, 05-01, Volume: 119, Issue:9 Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Databases, Factual; Death, Sudden, Cardiac; Defibrillators, Implantable; Electric Countershock; Female; Humans; Logistic Models; Male; Medicare Part D; Mexiletine; Ranolazine; Sodium Channel Blockers; Sotalol; Tachycardia, Ventricular; United States	2017
Pharmacological characterisation of electrocardiogram J-T European journal of pharmacology, 2022, Jul-15, Volume: 927 Topics: Animals; DNA-Binding Proteins; Electrocardiography; Flecainide; Guinea Pigs; Long QT Syndrome; Nifedipine; Quinidine; Quinine; Ranolazine; Sotalol; Torsades de Pointes; Verapamil	2022